Return to List
Results 1–5 of 5
Title Date
1.

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Number 606

ABSTRACT: Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding, and gynecologists may be consulted either before the initiation of cancer treatment to request strategi...

August 2014

PDF Format
2.

Primary Ovarian Insufficiency in Adolescents and Young Women

Number 605

ABSTRACT: Primary ovarian insufficiency is the depletion or dysfunction of ovarian follicles with cessation of menses before age 40 years. There is no consensus on criteria to identify primary ovaria...

July 2014

PDF Format
3.

OnabotulinumtoxinA and the Bladder

Number 604

ABSTRACT: In January 2013, the U.S. Food and Drug Administration approved the use of onabotulinumtoxinA (also known as Botox A) for the treatment of overactive bladder, thus providing another treatme...

June 2014

PDF Format
4.

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT: Tamoxifen, a nonsteroidal antiestrogen agent, is widely used as adjunctive therapy for women with breast cancer, and it has been approved by the U.S. Food and Drug Administration for adjuva...

June 2014

PDF Format
5.

Preexposure Prophylaxis for the Prevention of Human Immunodeficiency Virus

Number 595

Abstract: Preexposure prophylaxis is defined as the administration of antiretroviral medications to individuals who are not infected with human immunodeficiency virus (HIV) and are at the highest ris...

May 2014

PDF Format